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Abstract 
At present, only the United States and New Zealand allow direct-to-consumer advertising 
(DTCA) of prescription medicine. In other countries where DTCA is not allowed, including 
Australia and the United Kingdom, pharmaceutical companies undertake disease awareness 
advertising (DAA). In DAA, advertisements do not name a drug directly, but provide general 
information about diseases and treatments, and encourage consumers to talk to their doctor. 
Similar debate surrounds these two forms of advertising, yet while past research has explored 
consumers’ attitudes and behaviour in response to DTCA, little consideration has been given 
to DAA. This paper compares Australian consumers’ perceptions of DAA with New Zealand 
consumers’ perceptions of DTCA. Despite differences in the type and extent of advertising, 
respondents perceived similar benefits including heightened awareness of treatment options 
and improved discussions with doctors. New Zealand respondents associated many negative 
outcomes with DTCA including unbalanced information, inappropriate requests to doctors 
and consumer confusion. 
  
Introduction 
Direct to consumer advertising (DTCA) occurs when pharmaceutical companies promote 
prescription medicine brands to the general public, via mass media or other media including 
the Internet. An alternative, disease awareness advertising (DAA), occurs when 
pharmaceutical companies or other organizations (including the government and non-profit 
organizations) promote diseases or conditions, rather than named treatments (ANZTPA, 
2005). Pharmaceutical companies use DAA to promote diseases or conditions for which they 
produce a treatment, and typically do so in jurisdictions where DTCA is prohibited (Mintzes, 
2006). 
DTCA is currently legal in only two countries within the Organization for Economic 
Cooperation and Development (OECD), the United States (US) and New Zealand. There is 
on-going debate in both countries about the benefits of DTCA, growing concern about the 
potential harms it may cause (Toop et al., 2003; Moynihan and Bay, 2007), and speculation 
about its future (Royne and Myers, 2008). Other countries, including Canada, European 
Union and Australia, have considered introducing DTCA, and it remains a topical regulatory 
question in many countries (Gardner et al., 2003; Toop and Mangin, 2006, 2007).  
Questions about the benefits delivered by DTCA have focused attention on its origins and 
effects. Mandese (2005) suggested that the key beneficiaries of DTCA were media and 
advertising groups, both of which played important roles in its introduction, and have lobbied 
for more relaxed regulatory oversight. However, Donohue (2006) suggested DTCA had its 
genesis in the patients’ rights movement of the 1970s where it reflected a change from the 
‘learned intermediary’ model of healthcare to a partnership model. She suggested that DTCA 
capitalizes on consumers’ desire for empowerment, a point recognized by pharmaceutical 
companies, which have funded patient advocacy groups (Jacobson, 2005). Yet, while DTCA 
provides information, its profit motive continues to trouble medical and social researchers 
(Coney, 2002). 
Proponents of DTCA argue that it educates consumers about new medicines and the diseases 
these treat (Bonaccorso and Sturchio, 2002; Auton, 2004, 2007). Other benefits thought to 
accrue from DTCA include earlier diagnosis, more informed discussions with doctors, and 
increased compliance with treatment regimens (Auton, 2007). Recent studies suggest that 
DTCA also provides information to groups with lower health literacy, and so may help 
reduce health inequities (Kaphingst et al., 2005). However, Mintzes (2002) concludes that 
DTCA may mislead consumers by inflating the likely benefits they will receive from taking a 
treatment and downplaying the risks and side effects. Toop et al. (2003) extend this point and 
argue that DTCA creates an over-reliance on medications when behavioural or lifestyle 
changes may achieve better long-term outcomes. DTCA may not only promote less optimal 
treatment paths, but Toop and Mangin (2006) also suggest it may damage doctor–patient 
relationships by stimulating requests for advertised drugs that do not suit patients’ overall 
health profile. They conclude that the difficulty of dealing with poorly informed requests 
could reduce the high level of trust required between doctors and patients and result in 
misallocation of consultation time. 
In many countries where DTCA is not permitted, consumers are exposed to pharmaceutical 
company-sponsored DAA, which is designed to create awareness of diseases and the 
availability of treatments. For DAA, a similar debate over its ethics and effects has occurred 
(Glatter, 2004; Mintzes, 2006). Moynihan and Henry (2006) argue that, like DTCA, DAA 
will encourage healthy people to believe they may require potentially unnecessary tests or 
medication. In some instances, such as when a new treatment becomes available, 
pharmaceutical companies attempt to partner with disease support groups to undertake 
advertising and public relations activities. However, this can have negative implications if the 
risk profile of the treatment is not fully known, and because the advertising is portrayed as a 
community service its commercial intent is obscured (Mackenzie et al., 2007). For example 
in 2000, the Arthritis Foundation encouraged arthritis sufferers to ask their doctors about an 
exciting new treatment via a community service announcement on the only Australian non-
commercial television channel. This promotion occurred following a donation of $250 000 to 
the Arthritis Foundation by the makers of Celebrex (Searle and Pfizer) (Barry, 2000), but 
prior to the risks associated with cox-2 inhibitors being exposed. 
In other instances, pharmaceutical companies have been criticized for providing unbalanced 
information or exaggerating the prevalence or severity of a condition which may cause 
consumer anxiety and unnecessary visits to their doctor (Mintzes, 2006; Hall and Jones, 
2007; Hall, 2008). For example, one of a series of advertisements in Canada (produced by the 
manufacturers of a cholesterol-lowering medication) depicted a young, healthy man about to 
walk around the corner into the charge of a rhinoceros. The tagline for the advertisements 
was ‘Living with high cholesterol, you never know what’s around the corner’. The text 
describes the risk of death from heart attack, and while cholesterol is discussed, other risk 
factors (such as smoking, obesity and blood pressure) are omitted (Mintzes, 2006). The use of 
fear appeals in pro-social advertising has been criticized as they have been found to induce 
maladaptive responses such as chronic anxiety for those most at risk, or complacency for 
those not directly targeted (Hastings et al., 2004). 
There is concern that DAA circumvents the ban on DTCA because, while it does not include 
the name of a prescription medicine product, it often contains other branding techniques such 
as the use of logos or spokes-characters to communicate the identity of a product (such as the 
Pfizer tiger character used to promote Viagra). Further, DAA targeting consumers often 
coincides with branded promotions targeting medical professionals (Glatter, 2004; Hall and 
Jones, 2007).  
In contrast, proponents argue that DAA educates consumers about diseases and conditions, 
enables them to keep up to date with new treatments, and encourages those who are 
potentially at risk to visit their doctor (Wielondek, 2005; Angelmar et al., 2007). These 
arguments clearly reflect themes evident in the long-running debate over DTCA and raise 
questions about consumers’ perceptions of these different forms of pharmaceutical 
advertising. The current study examined Australian and New Zealand consumers’ perceptions 
of DAA and DTCA, respectively. The findings provide the first insights into how consumers 
respond to DAA, enable a comparison of consumers’ perceptions of DAAand DTCA, and 
may help to inform regulatory decisions about pharmaceutical promotions facing many 
developed nations. 
 
Advertising expenditure and media exposure  
Glatter (2004) suggests DTCA offers potential returns to manufacturers and Toop et al. 
(2003) recorded sharp spikes in prescriptions following DTCA campaigns. The US 
Government Accountability Office (GAO) reported a trend of increasing expenditure on 
DTCA. Although promotion to physicians still outweighed spending on DTCA, television 
and magazine DTCA increased at twice the rate of detailing to doctors during the 1997–2005 
period (US GAO, 2006). However, more recent data have indicated a slight drop in U.S. 
spend on DTCA between 2006 and 2007 ($US4.81 billion to $US4.77 billion) (IMS Health, 
2008). New Zealand data reflect these patterns; pharmaceutical companies spent an estimated 
$NZ38 million ($US30.5 million) on DTCA in 2006; this represented the largest category of 
advertising spending on therapeutic products (Ministry of Health, 2006a) and was a 217% 
increase on the $NZ17.5 million spent on DTCA in 1999. 
 Growth in expenditure on DTCA has been paralleled by an increase in consumer awareness. 
A recent US poll reported that 91% of respondents had heard or seen prescription drug 
advertisements (USA Today et al., 2008). Exposure occurs predominantly via television, 
which remains the dominant DTCA medium, although print media are also important 
(Brownfield et al., 2004; Hoek et al., 2004; Frosch et al., 2007). Wijesinghe and Norris 
(2008) reported that the frequency of medicine advertisements during 4 PM to 8 PM on New 
Zealand television in 2001 and 2006 had increased from 0.72 advertisements per hour to 1.14 
advertisements per hour. DTCA promotions declined as a proportion of medicine 
advertisements from 28% in 2001 to 17% in 2006, although this appears to reflect an increase 
in the number of over-the-counter (OTC) and complementary medicine promotions. 
In 2006, pharmaceutical companies in Australia spent an estimated $AUD190–200 million on 
mass media advertising (Nielsen Media Research AdEx, 2006); however, it is difficult to 
ascertain how much of this was spent on DAA as this figure includes OTC advertising. In 
Europe, it was estimated that spending on DAA would grow to $US345.5 million in 2008 
(Mintzes, 2006). 
Despite the limited literature on consumers’ responses to DAA, there is some evidence that 
this advertising increases awareness of the advertised health conditions and prescriptions of 
the sponsor’s product (Basara, 1996; t’Jong et al., 2004). A recent content analysis examined 
the prevalence of DAA in top circulating Australian women’s magazines and concluded it 
constituted approximately 12% of all therapeutic advertisements (Hall et al., 2009); this 
finding suggests its potential exposure is at least moderate.  
 
Regulation 
The US Food and Drug Administration (FDA) regulates and oversees DTCA. The FDA has 
an explicit ‘fair balance’ criterion that requires information about a drug’s benefits be 
balanced by information about its potential risks and side effects (Hoek et al., 2004). Despite 
this criterion, recent content analyses have questioned whether this balance is achieved, 
particularly in television advertisements (Kaphingst et al., 2004; Macias et al., 2007), and the 
GAO had doubts about the adequacy of consumer protection FDA regulation afforded (US 
GAO, 2006). 
Critics of the US regulatory model suggest self-regulation is more efficient than government 
regulation and makes no demands on taxpayer funds (Calfee, 2002). New Zealand relies on 
such a system and the advertising industry is responsible for developing codes of practice and 
administering the complaints body that adjudicates complaints (Hoek and Gendall, 2002). 
The New Zealand system evolved rapidly in response to concerns raised by politicians and 
health professionals following DTCA’s emergence in the late 1980s, and rapid growth during 
the late 1990s. Following the development of a self-regulatory code, the Advertising 
Standards Authority devised a pre-vetting system to improve compliance with the code. 
Complaints about all advertising can be made to the Advertising Standards Complaints 
Board, which adjudicates these (Advertising Standards Authority New Zealand, 2008). 
Despite these measures, DTCA has generated considerable concern and leading health 
professionals called on the New Zealand Minister of Health to review the regulatory lacunae 
that enabled DTCA to flourish. Two reviews conducted by the New Zealand Ministry for 
Health (Ministry of Health, 2000, 2006a) received polarized submissions. In the 2006 
Review, submissions by advertising and pharmaceutical industries favoured retaining DTCA 
under a liberal self-regulatory system. However, the majority of submitters supported a 
complete ban on DTCA because they felt there was inconclusive evidence that DTCA 
provides a public health benefit, and that purported benefits were outweighed by potential 
harms (Ministry of Health, 2006b). The majority of submitters were concerned that DTCA 
led to consumer confusion, and many expressed the need to provide balanced and 
independent health information. Submitters also supported removal of for-profit disease-state 
advertising as many felt there was little difference between this and DTCA, and that disease 
advertising allowed companies to promote products in a less transparent way (Ministry of 
Health, 2006b). 
In Australia, the Therapeutic Goods Act prohibits advertising of prescription medicines 
directly to consumers (Australian Government Department of Health and Ageing, 2007). 
However, the development of a Trans-Tasman regulatory scheme for therapeutic products 
with New Zealand (the Australian New Zealand Therapeutic Products Authority or 
ANZTPA) led to speculation that Australia would allow DTCA, although this has not yet 
eventuated. Currently, Australian pharmaceutical companies target consumers via DAA and 
unbranded product advertisements, neither of which include the brand name of the 
prescription medicine indicated for the disease or health condition (Hall and Jones, 2007). 
Medicines Australia, an industry body, monitors this advertising and provides a complaints 
service, but does not vet or otherwise restrict placement of DAA (Medicines Australia, 2009). 
The fact that pharmaceutical advertising has emerged in different guises, is subject to 
different regulatory systems, and yet stimulates similar debate, suggests that further research 
exploring consumers’ perceptions of pharmaceutical promotions would provide regulators 
with a more robust evidence base to inform their decisions. The following section reviews 
existing evidence on US and New Zealand consumers’ views of DTCA. 
 
Consumer perceptions 
Existing research suggests US and New Zealand consumers hold generally positive attitudes 
toward DTCA and believe it provides them with useful information about health conditions 
and treatments, and facilitates discussions with doctors (Mehta and Purvis, 2003; Deshpande 
et al., 2004; Hoek et al., 2004). However, consumers are more ambivalent about the overall 
worth of DTCA, particularly its role in improving the decisions they make about their health 
(Hoek et al., 2004; USA Today et al., 2008). Recent surveys in the US have found growing 
negative attitudes towards DTCA, including a dislike of advertisement content and the 
perceived ubiquity of DTCA (Friedman and Gould, 2007a; USA Today et al., 2008). 
A US survey of 1695 adults found that 67% of respondents felt DTCA provided education 
about treatments and encouraged people to seek help for conditions or diseases about which 
they had been previously unaware (USA Today et al., 2008). These findings are generally 
similar to those reported in New Zealand, where a survey of 625 residents found that 91% 
believed DTCA helped make people aware of new medicines (Hoek et al., 2004). Between 
half and two thirds of New Zealand respondents found DTCA useful (61%), and thought it 
helped people have better discussions with their doctors (64%); however, only half felt it 
helped people to make better decisions about their health (52%).  
Friedman and Gould (2007a) surveyed 321 US residents and reported high awareness of 
DTCA (96%), but noted some negativity towards it; over half reported that they disliked 
seeing advertisements for prescription drugs. Nevertheless, 59% still agreed that, overall, 
DTCA was a good thing (Friedman and Gould, 2007a). In a USA Today survey, 53% of 
adults thought prescription drug advertising was a good thing, however 68% felt that DTCA 
appeared too frequently on television and 66% felt it encouraged people to take medications 
that they did not really need (USA Today et al., 2008). 
Studies of more specific population groups have reported similar findings. DeLorme et al. 
(2007) conducted in-depth interviews with older Americans (n=25) to explore their views of 
DTCA. While these participants thought DTCA affected others more than themselves, they 
nevertheless paid attention to DTCA, and believed it helped them learn about drug benefits 
and risks, and assisted them to locate further information. However, they noted that DTCA 
lacked balance, portrayed unrealistic outcomes and created pressure on viewers to talk with 
their doctors. Respondents also complained about the quantity and frequency of DTCA 
(DeLorme et al., 2007). 
Because DTCA does not exist in Australia, work exploring consumers’ likely responses has 
been hypothetical. Miller and Waller (2004) surveyed 619 individuals and reported that 53% 
felt DTCA would provide useful information while 58% felt it would make the public more 
aware of the benefits prescription medicines could offer (Miller and Waller, 2004). However, 
only 32% agreed that it was proper for prescription medicines to be advertised, and almost 
half (48%) felt that DTCA would not improve the quality of prescription medicines available 
in the future (Miller and Waller, 2004). These findings are consistent with Vatjanapukka and 
Waryszak (2004) who reported mixed responses to DTCA, particularly among those more 
knowledgeable about prescription medicines. Jones and Mullan’s (2006) analysis of older 
Australians’ views also concluded that participants held ambivalent views about DTCA; 
while they recognized it could inform their discussions with doctors, they also thought it 
could be confusing and promote reliance on medications. 
 
Current Study 
Till date, no studies have compared whether consumers exposed to DTCA differ in their 
perceptions and behaviours from those exposed to DAA. This omission is serious, since 
global trade and economic alliances are becoming more prevalent and assume a high level of 
regulatory congruence. New Zealand and Australia have close economic relations and their 
governments have actively promoted stronger trade relationships. Advertising of prescription 
medicines in both countries is self-regulated via industry codes of conduct and a complaints 
process (Advertising Standards Authority New Zealand, 2009; Medicines Australia, 2009). 
Despite their physical proximity, New Zealand and Australia have very little cross-border 
advertising, thus the media environments are largely insulated from each other. 
The current study examined Australian and New Zealand consumers’ general perceptions of 
DAA and DTCA, respectively, and determined perceived benefits or weaknesses of these 
advertising formats. The natural experiment created by New Zealand and Australia’s 
differing stance on DTCA enables development of an evidence base that may be useful for 
countries currently reviewing their position on prescription pharmaceutical advertising, such 
as Canada and Europe. 
 
Methodology 
The Australian survey questionnaire was conducted in 2006 and questions were based on 
surveys previously developed and tested by Hoek et al. (2004) and Hoek and Gendall (2004) 
to elicit consumer responses to DTCA in New Zealand in 2002 and 2003, respectively. The 
New Zealand questionnaire was part of a broader survey conducted in 2006 to examine New 
Zealanders’ views on advertising and how this should be regulated. The questions relating to 
prescription medicine were based on those previously used by Hoek et al. (2004) and Hoek 
and Gendall (2004). Although both surveys were based on existing instruments, there were 
minor differences in the question wording and the scales used. 
The Australian sampling frame was a purchased database of mail addresses for a 
metropolitan area in New South Wales. A total of 2800 addresses were randomly sampled, 
and a pretest was administered randomly to 400 of these addresses. The pretest resulted in 56 
responses (response rate of 14%), following which minor modifications were made to the 
wording of one question. The remaining 2400 addresses were sent the revised survey 
questionnaire.  
The New Zealand sample were 2000 people randomly selected from the electoral roll 
(registration to vote is mandatory in New Zealand, thus the electoral roll is a comprehensive 
database of adults aged 18 years and over).  
Results 
For the Australian survey, a total of 357 surveys were returned (representing a response rate 
of 15%); all responses were used along with those from the pretest, resulting in a total of 413 
responses. For the New Zealand survey, a total of 998 respondents completed and returned 
their survey (after deducting ineligible and gone-no-address returns, this represents a valid 
response rate of 56%). Data from both surveys were weighted so the samples’ age–sex 
distributions matched census data; the Australian data matched the metropolitan area from 
which the sample was drawn and is similar to the national age–gender profile, while the NZ 
data matched the national age–gender profile. The following section reports on Australian 
and New Zealand consumers’ perceptions of DAA and DTCA, respectively. 
 
Australian perceptions of DAA 
Australian participants were asked whether they agreed or disagreed with nine general 
statements about DAA (see Table 1) on a five-point agree–disagree scale. Agree and strongly 
agree responses were aggregated. Most respondents (80%) agreed that DAA makes people 
aware of disease/conditions and different treatment options and almost two thirds agreed that 
DAA helps people to have better discussions with their doctors. While 62% agreed that DAA 
is designed to increase positive health behaviours such as diet and exercise, some respondents 
may have considered government public health and non-government sponsored 
advertisements as well as those sponsored by pharmaceutical companies; thus this estimate 
may be higher than if respondents had considered only pharmaceutical company sponsored 
DAA. Just over half (52%) felt that DAA helps them to make better decisions about their 
health. 
 
 
Table 1 Australian responses to statements regarding DAA 
Statements % Agreement 
(inc. strongly 
Agree  + 
agree) 
(n=413) 
Advertisements help make people aware of disease/conditions and different 
treatment options 
80 
 
Advertisements alert people to disease in order to sell more medicine or 
medical products 
72 
 
Advertisements about diseases/conditions help people have better 
discussions with their doctor 
65 
 
Advertisements alert people to disease in order to increase positive health 
behaviours such 
as diet or exercise 
62 
 
Advertisements about diseases/conditions help people make better decisions 
about their health 
52 
 
Advertisements alert people to disease in order to make the disease itself 
more important 
43 
 
Advertisements alert people to disease in order to increase visits to doctors 
or other 
health professionals 
40 
 
Advertisements about diseases/conditions confuse people about what 
disease they may be 
at risk of developing 
36 
 
Advertisements about diseases/conditions are often difficult to understand 26 
 
When considering DAA’s intent, 72.2% agreed that this advertising was designed to sell 
more medicine or medical products, and around 40% agreed that it was to make the disease 
itself seem more important or to increase visits to doctors. Over a third (36%) felt that DAA 
confuses people about what diseases they may be at risk of developing, while just over one 
quarter (26%) felt that advertisements about diseases and conditions are often difficult to 
understand. 
 
New Zealand perceptions of DTCA 
To explore respondents’ views on DTCA, New Zealand participants were asked the extent to 
which they agreed or disagreed with 11 general statements (see Table 2) on a four point 
agree–disagree scale. Agree and strongly agree responses were aggregated. Most respondents 
(84%) agreed that DTCA overemphasizes drug benefits and most thought DTCA does not 
provide balanced information about the risks and benefits of the medicine. Half agreed that 
people probably feel confused by the information given in DTCA. The majority (78%) 
believed that prescription medicine advertising makes people more aware of options to treat 
their health problems; however, over 80% considered that most people lack the technical 
knowledge required to tell whether an advertised medicine is safe for them. Nearly two thirds 
agreed that advertising for prescription medicines helps people have more informed 
discussions with their doctor; however, a similar proportion thought DTCA leads people to 
ask their doctor for medicines that may not suit them. Over half believed that DTCA makes 
people rely more on medicines to treat their health conditions, though only 12% thought it 
harms the relationship that patients have with their doctor.  
Sixty per cent of New Zealand respondents agreed that it would be better to spend the money 
that is used to regulate prescription medicine advertising on a neutral information service. 
There was a strong preference for a government agency to manage regulation of prescription 
medicine advertising (33%), followed by an independent group (15%), the advertisers and the 
media (6%) and just under a fifth (17%) of New Zealand respondents thought that the 
advertising of prescription medicines should not be allowed; the remainder were either unsure 
(8%) or in favour of a combination of a government agency, independent group and 
advertisers and the media to manage prescription medicine advertising (21%). 
 
Discussion 
Despite the differences in the questions and scales of the surveys conducted in either country, 
as well as differences in the types of pharmaceutical advertising, there are several similarities 
between the Australian and New Zealand results. 
 
Generating awareness 
Very similar proportions of both samples agreed that the purpose of DAA and DTCA is to 
make people aware of health conditions and treatment options. These findings are similar to 
US surveys, which reported high levels of agreement with the proposition that DTCA helps 
increase awareness of options or new medicines (Hoek et al., 2004; USA Today et al., 2008). 
Similar proportions of Australian and New Zealand respondents reported feeling informed 
about treatment options, irrespective of whether they saw DAA or DTCA. This suggests that 
in Australia, even unbranded promotions create high levels of treatment awareness. 
 
Table 2 New Zealand responses to statements regarding DTCA 
Statements % Agreement 
(inc. strongly 
Agree + agree) 
(n=998) 
Prescription medicine advertisements over-emphasize the benefits and do 
not explain the risks enough 
83 
Most people lack the technical knowledge to tell whether an advertised 
medicine is safe 
81 
Advertising for prescription medicines makes people more aware of 77 
options that could treat 
their health problems 
Advertising for prescription medicines leads people to ask their doctor for 
medicines that may not be suitable 
67 
Advertising for prescription medicines helps people have more informed 
discussions with their doctor 
64 
It would be better if money spent on regulating prescription medicine 
advertising was used to provide a neutral information service 
60 
Advertising for prescription medicines makes people rely more on 
medicines to treat health conditions 
54 
Most people probably understand the information in advertisements for 
prescription medicines 
48 
Most people probably feel confused by the information in advertisements 
for prescription medicines 
47 
Prescription medicine advertisements provide balanced information about 
a medicine’s risks and benefits 
26 
Advertising for prescription medicines harms the relationship patients 
have with doctors 
12 
 
Health decisions and health behaviour 
Australians exposed to DAA were ambivalent about whether these advertisements help them 
to make better health decisions, which is similar to results relating to DTCA from earlier New 
Zealand and US consumer surveys (see Hoek et al., 2004). More recent findings suggest 
views towards DTCA as an information source have become more negative in the US; for 
example, Friedman and Gould (2007a) reported that only 41% of their respondents agreed 
that DTCA helped them to make better decisions about their health (Friedman and Gould, 
2007a). Furthermore, only 19% of physicians thought DTCA assisted their patients to make 
better health decisions (Friedman and Gould, 2007b). 
While the results revealed some similar patterns, important differences were also evident. For 
example, while 55% of New Zealand respondents felt that DTCA makes people rely more on 
medicines to treat medical conditions, 62% of Australian respondents felt that DAA is 
designed to increase other positive health behaviours such as diet and exercise. Although 
New Zealand respondents were not asked about the potential lifestyle benefits that DTCA 
might promote, the proportion who felt DTCA offered a ‘pill for every ill’ suggests fewer 
would be likely to agree that DTCA brought wider benefits. Only 40% of Australian 
respondents felt that DAA was designed to encourage consumers to visit a doctor or health 
professional, even though Medicines Australia stipulates that this information must be 
included in DAA (Medicines Australia, 2009). A high proportion of New Zealand 
respondents agreed that DTCA would prompt consumers to ask for drugs that may not suit 
them. This implies that studies examining the influence of pharmaceutical promotions on 
interactions with health professionals should also explore the types of requests that would be 
made and the likely health benefits that would ensue.  
 
Interaction with doctor  
The majority of respondents in both countries (65%) agreed that pharmaceutical advertising 
improves discussions with their doctor. These proportions are similar to those reported in 
earlier New Zealand surveys, which in turn are very similar to US survey results. Just under 
two thirds of respondents in these countries (64% New Zealand and 61% US) felt that DTCA 
helps people to have better discussions with their doctor about their health (Hoek et al., 
2004). Murray et al. (2004) surveyed 3209 US residents and found DTCA encourages 
patients to disclose health concerns to their doctors and helps some to feel more confident 
and in control of their consultation. While studies into US physicians’ attitudes concur that 
DTCA may help patients to initiate discussions with their doctor (Murray et al., 2003; 
Weissman et al., 2004), Friedman and Gould (2007b) found only 27% of the 416 physicians 
they surveyed felt DTCA gave patients adequate information to decide whether to discuss a 
drug with their doctor. 
Over two-thirds of the New Zealand respondents (68%) felt DTCA led to requests to doctors 
for medicines that may not be appropriate, an identical finding to the 2008 USA Today poll. 
Studies of US physicians’ attitudes have found that around 80% felt DTCA led to 
inappropriate requests for unnecessary prescriptions (Friedman and Gould, 2007b; Weissman 
et al., 2004). Toop et al. (2006) argue that responding to such requests and re-educating 
patients can detract from valuable consultation time; this problem requires further research to 
assess whether other adverse outcomes result. Twelve per cent of New Zealand respondents 
agreed that DTCA harms the doctor–patient relationship; this is a higher proportion than 
Murray et al. (2004) reported; their US work estimated that only 5% of respondents who took 
DTCA information to their doctors thought this had negatively affected their relationship. 
 
Consumer understanding of advertising 
Nearly three quarters of Australian respondents (72%) agreed that DAA aimed to sell more 
treatments (or medical products). These results imply Australians are aware that DAA has a 
profit motive and may allay concerns that consumers falsely perceive DAA to be a 
community service. However, further research is required to determine how Australian 
consumers respond to actual DAA with varying sponsors before these concerns can be put 
aside. Similar research could be undertaken in New Zealand, particularly given that 60% of 
respondents felt resources spent on regulating DTCA could be better spent providing neutral 
drug information. 
With regard to the confusion caused by advertisements, 48% of New Zealand respondents 
thought that most people felt confused by the information in DTCA. In contrast, 36% of 
Australian respondents felt that DAA confused people about the disease they may be at risk 
of developing. However, New Zealand respondents were almost twice as likely to report 
difficulties in understanding DTCA (49%) than Australians (26%). This result may reflect the 
more detailed product information required in DTCA, which includes technical details that 
lay people are unlikely to understand; this interpretation is supported by the finding that 81% 
of New Zealand respondents agreed most people lacked the technical knowledge to judge the 
safety of an advertised product. 
These findings are supported by previous studies identifying the potential of pharmaceutical 
promotions to mislead or confuse consumers (Kaphingst and DeJong, 2004; Jones and 
Mullan, 2006). Our findings also support earlier recommendations to improve DTCA, 
including requiring a more effective balance of risk and benefit information (Kaphingst et al., 
2004) and presenting important risk information in a stand-out window format (Stotka et al., 
2007). Use of more quantitative data to support benefit claims and reducing emotional 
appeals that suggest a disease is more prevalent or a drug more efficacious than is really the 
case would also help to increase the ease with which lay consumers understand DTCA 
(Woloshin et al., 2001; Woloshin and Schwartz, 2006). Finally, the use of consumer friendly 
language is recommended to promote understanding and reduce the demands on doctors 
(Handlin et al., 2003; Kaphingst et al., 2004).  
 
Limitations 
A significant limitation of the Australian survey is the low response rate, which may result in 
a level of non-response bias. Another limitation previously mentioned is that Australian 
respondents may have considered government or non-government sponsored DAA or even 
OTC advertising when responding to the questions regarding DAA, and thus responses 
specific to pharmaceutical company sponsored DAA for prescription medicines may differ. 
The two surveys used different sampling methods, different measurement scales and different 
questions; however, as the purpose of the research was to compare general perceptions of 
DAA and DTCA, the questions needed to reflect the different regulatory environments and 
the data were suitable for comparisons outlined. 
 
Conclusion and Future Research 
Australian and New Zealand consumers value DAA and DTCA for generating awareness of 
disease and treatment options and improving discussions with their doctors. Overall, 
Australian consumers found DAA less confusing than New Zealanders found DTCA, 
although further work is required to test how exposure to DAA and DTCA, respectively, 
influences consumers’ understanding and knowledge. Respondents were ambivalent about 
whether pharmaceutical advertising improved their decision making and a neutral 
information service may be a more effective means of improving their knowledge of diseases 
and treatment options.  
An area of growing interest is healthcare websites, with a Nielsen online custom survey in 
2008 finding more than 80% of internet users seek healthcare information online and report 
high levels of trust in the written content of websites (The Nielsen Company, 2010). The 
presence of pharmaceutical company-sponsored disease awareness websites appears to be 
increasing, and a recent study of Australian general practitioners found that close to half had 
recommended such websites to their patients after receiving incentives or enticements from 
pharmaceutical companies (Usher and Skinner, 2009). There is concern regarding health 
information on the internet as searches for common symptoms can result in consumers 
experiencing considerable anxiety and unnecessarily engaging health professionals (White 
and Horvitz, 2009). ‘Cyberchondria’ is defined as ‘the unfounded escalation of concerns 
about common symptomatology, based on the review of search results and literature on the 
Web’ (White and Horvitz, 2009: p. 23:2). Further research should consider whether 
pharmaceutical company websites increase cyberchondria and medicalization, as well as 
consumer demand for pharmacological treatments. 
For DAA and DTCA, benchmark studies are needed into consumer responses to these 
different forms of advertising to determine how they influence consumers’ behaviour and 
public health outcomes. From this, longitudinal studies could more accurately measure the 
influence of advertising and differing advertising regulation to better inform future health 
policy. Future work examining information credibility, the trust respondents place in different 
sources, and the likelihood they would use information from these, will also be important as 
decisions regarding the adoption and continuation of DAA and DTCA are made. Perhaps 
most critically, however, future research should also locate consumers’ views within the 
broader ethical and economic debate over prescription medicine promotions and the optimal 
means of providing consumers with information that is in their best interests. 
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